The Centre for Dermatology

Richmond Hill, Ontario L4B1A5

2 studies enrolling now · 33 studies all time

What they study most

Acne Inversa, Acne Vulgaris, Active Non-segmental Vitiligo, Alopecia Areata, Atopic Dermatitis, Chronic Plaque Psoriasis, Dermatitis, Atopic, Moderate Psoriasis, Plaque Psoriasis, Psoriasis, Psoriasis (PsO), Severe Psoriasis

Studies at this site

• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) — Recruiting now
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis — Recruiting now
• A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) — Completed
• A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Stopped early
• A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) — Completed
• A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Running, not enrolling
• A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis — Completed
• A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis — Completed
• Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis — Running, not enrolling
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis — Completed
• Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis — Completed
• A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis — Completed
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) — Completed
• A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa — Completed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) — Completed
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis — Completed
• Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis — Completed
• This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is — Completed
• Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy — Completed
• A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects — Completed
• A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris — Completed
• A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris — Completed
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata — Completed
• Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis — Completed
• Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis — Completed
• Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis — Completed
• Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis — Completed
• Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis — Completed
• A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis — Completed